The agency’s reasoning included the patient population for the trial, which the FDA said was low-risk and may not have truly needed an autograft or the Augment Bone Graft. In order to receive approval in the future, Wright Medical will need to prove patients in the trial are high-risk, according to the report.
More Articles on Devices:
Medtronic Acquires Cardiocom Disease Management Company for $200M
RTI Surgical’s Biologic Bone Graft Implanted in First Human Subject
SBi Launches Charcot Foot Solutions Website
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
